Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression

  title={Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression},
  author={Françoise Radat and Ivan Berlin and Odile Spreux-Varoquaux and Skander Elatki and Maurice Ferreri and Alain Jacques Puech},
It is generally accepted that the clinical efficacy of monoamine oxidase inhibitors (MAOI) is related to inhibition of this enzyme. In order to evaluate the predictive ability of monoamine oxidase-A inhibition for therapeutic efficacy, the start of treatment effects of moclobemide, a selective, reversible monoamine oxidase-A inhibitor, on plasma concentrations of monoamines and monoamine metabolites were determined. The plasma levels of 3,4-dihydroxy-phenylglycol (DHPG, deaminated metabolite of… Expand
Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157
CX157 is the first agent in the RIMA class with documented reversible inhibition of human brain MAO-A, supporting its classification as a R IMA, and the first RIM a with observed plasma levels that can serve as a biomarker for the degree of brain MAo-A inhibition. Expand
Reduced Monoamine Oxidase A Activity in Pregnant Smokers and in Their Newborns
BACKGROUND Tobacco smoking is associated with reduced monoamine oxidase A (MAOA) activity. Smoking-associated low MAOA activities in pregnancy and in newborns may have negative perinatal andExpand
Platelet Serotonin Level Predicts Survival in Amyotrophic Lateral Sclerosis
The positive correlation between platelet serotonin levels and survival strongly suggests that serotonin influences the course of ALS disease. Expand
Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III) : Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy
This work aims to provide real-time information about the nervous systems of children aged under the age of five and to provide a scaffolding for future generations to understand the nervous system. Expand


Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
It is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man. Expand
Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
Neither moclobemide nor toloxatone altered memory function, vigilance, subjective feelings or sleep characteristics of the subjects. Expand
Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines
A new methodological approach might represent a comfortable alternative to HPLC procedures in pharmacokinetic studies on reversible MAO inhibitors and plasma biogenic amines and their metabolites might be indicative of the biologic activity of moclobemide. Expand
Biochemistry and pharmacology of moclobemide, a prototype RIMA
Moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro, which accounts for the dose-dependent duration of in vivo enzyme inhibition of 12–24 h. Expand
The role of monoamine oxidase A in the metabolism and function of noradrenaline and serotonin
Monoamine oxidase (MAO) inhibitors were among the first psychotropic drugs to be discovered and introduced into clinical use either alone or in combination with serotonin (5-hydroxytryptamine) (5-HT)Expand
Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression
The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented and it is shown that reversible inhibitors of MAO‐A demonstrate good efficacy independently of the diagnostic category of depression. Expand
Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations
Single oral doses of 300, 450 and 600 mg moclobemide demonstrated marked inhibition of MAO-A activity, whereas a single dose of 300 mg induced a near-maximum effect. Expand
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
The reversed-phase liquid-chromatographic method is rapid, reliable, and simple, and it provides a more comprehensive assessment of noradrenergic nervous function than does measurement only of catecholamines. Expand
Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex
The results indicate that cerebrocortical noradrenaline release increases gradually during chronic MAO inhibition, which may be the result of more complete inhibition of the enzyme with time, not detectable by the ex vivo assay, but shown by the progressive reduction in metabolite levels. Expand
Monoamine oxidase A and B activities in heavy smokers
It is concluded that the activities of both forms of the MAO are reduced in heavy dependent smokers. Expand